DPDoctor's PassportEducation
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
RapidMLAMSRAFoundation

Solitary pulmonary nodule and incidental lung findings

Essential points for quick revision.

Synopsis

Turn an incidental pulmonary nodule into a proportionate, documented pathway using prior imaging, CT phenotype and validated malignancy risk while addressing other actionable thoracic findings.

  • A pulmonary nodule is an imaging description, not a diagnosis; first confirm that the apparent opacity is intrapulmonary and characterise it on thin-section CT.
  • Retrieve all prior chest imaging before ordering serial scans because long-term stability, true growth or a previously overlooked lesion can change the pathway immediately.
  • Risk assessment integrates age, smoking, cancer history, nodule size, morphology and location; use the BTS-endorsed Brock model in its intended population rather than intuition alone.

Key red flags

Haemoptysis, a central obstructing lesion, lobar collapse, suspicious lymphadenopathy or a rapidly enlarging mass should enter an urgent lung-cancer pathway rather than routine nodule surveillance.

Investigation priorities

01
Prior imaging reviewFirst step

Establish whether the lesion is new, stable or genuinely growing.

Management branches

CHARACTERISEBuild a reliable starting phenotype

A chest radiograph or CT report describes a new solitary or multiple pulmonary nodule.

  1. Retrieve prior imaging and clinical context, including smoking, earlier malignancy, immune status, symptoms and whether an acute infective process is plausible.
  2. Obtain or reconstruct appropriate thin-section CT, documenting number, attenuation, morphology, lobe, dimensions or volume and every relevant non-nodule finding.
Open full textbook Answer 2 questions
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom